N1站淋巴结检出数目对pT1~3N0M0非小细胞肺癌患者预后的影响

目的:探讨N1站淋巴结检出数目与pT1~3N0M0非小细胞肺癌(NSCLC)患者临床病理特征及预后的关系。方法:选择2013年1月至2015年3月在安徽医科大学附属省立医院接受肺癌根治术的pT1~3N0M0 NSCLC患者337例,采用受试者工作特征(ROC)曲线的分析确定以N1站淋巴结检出数目预测pT1~3N0M0 NSCLC患者5年生存的最佳界值,根据最佳界值分组,分析N1站淋巴结检出数目与pT1~3N0M0 NSCLC患者临床病理特征及预后的关系。结果:337例患者共检出N1站淋巴结1 321枚,每例患者平均3.9枚。中位生存时间为42.0个月,1、3、5年生存率分别为82.2%、57....

Full description

Saved in:
Bibliographic Details
Published in中华肿瘤杂志 Vol. 44; no. 2; pp. 155 - 159
Main Authors 王高祥, 李田, 徐世斌, 王君, 熊燃, 徐美青, 解明然
Format Journal Article
LanguageChinese
Published 安徽医科大学附属省立医院 中国科学技术大学附属第一医院胸外科,合肥 230001 23.02.2022
Subjects
Online AccessGet full text
ISSN0253-3766
DOI10.3760/cma.j.cn112152-20200331-00284

Cover

Abstract 目的:探讨N1站淋巴结检出数目与pT1~3N0M0非小细胞肺癌(NSCLC)患者临床病理特征及预后的关系。方法:选择2013年1月至2015年3月在安徽医科大学附属省立医院接受肺癌根治术的pT1~3N0M0 NSCLC患者337例,采用受试者工作特征(ROC)曲线的分析确定以N1站淋巴结检出数目预测pT1~3N0M0 NSCLC患者5年生存的最佳界值,根据最佳界值分组,分析N1站淋巴结检出数目与pT1~3N0M0 NSCLC患者临床病理特征及预后的关系。结果:337例患者共检出N1站淋巴结1 321枚,每例患者平均3.9枚。中位生存时间为42.0个月,1、3、5年生存率分别为82.2%、57.1%和24.9%。ROC曲线分析显示,以N1站淋巴结检出数目预测pT1~3N0M0 NSCLC患者5年生存的最佳界值4.5枚,取整数后,以N1站淋巴结检出数目为5枚作为界值,将患者分为检出淋巴结<5枚组(212例)和检出淋巴结≥5枚组(125例)。检出淋巴结≥5枚组接受辅助化疗的患者比例为19.2%,高于检出淋巴结<5枚组(9.0%, P=0.007),两组患者其他临床病理特征差异均无统计学意义(均 P>0.05)。检出淋巴结<5枚组患者的中位生存时间为38.0个月,1、3、5年生存率分别为80.1%、52.5%和15.6%。检出淋巴结≥5枚组患者的中位生存时间为48.0个月,1、3、5年生存率分别为85.6%、64.0%和36.0%。检出淋巴结≥5枚组患者的生存率优于检出淋巴结<5枚组( P=0.002)。多因素Cox回归分析显示,T分期( OR=1.408,95% CI为1.118~1.670)和N1站淋巴结检出数目( OR=0.670,95% CI为0.526~0.853)是pT1~3N0M0 NSCLC患者预后的独立影响因素。 结论:N1站淋巴结检出数目与pT1~3N0M0 NSCLC患者的预后有关,术后病理检查时至少检出5枚N1站淋巴结能提高患者的5年生存率。
AbstractList 目的:探讨N1站淋巴结检出数目与pT1~3N0M0非小细胞肺癌(NSCLC)患者临床病理特征及预后的关系。方法:选择2013年1月至2015年3月在安徽医科大学附属省立医院接受肺癌根治术的pT1~3N0M0 NSCLC患者337例,采用受试者工作特征(ROC)曲线的分析确定以N1站淋巴结检出数目预测pT1~3N0M0 NSCLC患者5年生存的最佳界值,根据最佳界值分组,分析N1站淋巴结检出数目与pT1~3N0M0 NSCLC患者临床病理特征及预后的关系。结果:337例患者共检出N1站淋巴结1 321枚,每例患者平均3.9枚。中位生存时间为42.0个月,1、3、5年生存率分别为82.2%、57.1%和24.9%。ROC曲线分析显示,以N1站淋巴结检出数目预测pT1~3N0M0 NSCLC患者5年生存的最佳界值4.5枚,取整数后,以N1站淋巴结检出数目为5枚作为界值,将患者分为检出淋巴结<5枚组(212例)和检出淋巴结≥5枚组(125例)。检出淋巴结≥5枚组接受辅助化疗的患者比例为19.2%,高于检出淋巴结<5枚组(9.0%, P=0.007),两组患者其他临床病理特征差异均无统计学意义(均 P>0.05)。检出淋巴结<5枚组患者的中位生存时间为38.0个月,1、3、5年生存率分别为80.1%、52.5%和15.6%。检出淋巴结≥5枚组患者的中位生存时间为48.0个月,1、3、5年生存率分别为85.6%、64.0%和36.0%。检出淋巴结≥5枚组患者的生存率优于检出淋巴结<5枚组( P=0.002)。多因素Cox回归分析显示,T分期( OR=1.408,95% CI为1.118~1.670)和N1站淋巴结检出数目( OR=0.670,95% CI为0.526~0.853)是pT1~3N0M0 NSCLC患者预后的独立影响因素。 结论:N1站淋巴结检出数目与pT1~3N0M0 NSCLC患者的预后有关,术后病理检查时至少检出5枚N1站淋巴结能提高患者的5年生存率。
Abstract_FL Objective:To investigate the relationship between the examined number of lymph nodes at the N1 station and the clinicopathological characteristics and prognosis of patients with pT1-3N0M0 non-small cell lung cancer (NSCLC).Methods:A total of 337 patients with pT1-3N0M0 NSCLC who underwent radical lung cancer surgery at the Provincial Hospital Affiliated to Anhui Medical University from January 2013 to March 2015 were selected. The receiver operating characteristic (ROC) curve analysis was used to determine the optimal cut-off value for predicting 5-year survival in pT1-3N0M0 NSCLC patients by the examined number of lymph nodes at the N1 station. The relationships between the examined number of lymph nodes at the N1 station and the clinicopathological characteristics and prognosis of patients with pT1-3N0M0 NSCLC were analyzed according to the optimal cut-off group.Results:A total of 1 321 lymph nodes at N1 station were examined in 337 patients, with a mean of 3.9 nodes per patient. The median survival time was 42.0 months, with 1-, 3- and 5-year survival rates of 82.2%, 57.1% and 24.9%, respectively. ROC curve analysis showed that the optimal cut-off value of 4.5 lymph nodes examined at the N1 station was used to predict 5-year survival in patients with pT1-3N0M0 NSCLC. After rounding off the number, the number of lymph nodes examined at the N1 station was 5 as the cut-off value, and the patients were divided into the group with <5 lymph nodes examined (212 cases) and the group with ≥5 lymph nodes examined (125 cases). The proportion of patients received adjuvant chemotherapy was 19.2% in the group with ≥5 lymph nodes examined, which was higher than 9.0% in the group with <5 lymph nodes examined ( P=0.007), and the differences in other clinicopathological characteristics between the two groups were not statistically significant ( P>0.05). The median survival time for patients in the group with <5 lymph nodes examined was 38.0 months, with 1-, 3- and 5-year survival rates of 80.1%, 52.5% and 15.6%, respectively. The median survival time for patients in the group with ≥5 lymph nodes examined was 48.0 months, and the 1-, 3- and 5-year survival rates were 85.6%, 64.0% and 36.0%, respectively. The survival rate of patients in the group with ≥5 lymph nodes examined was better than that in the group with <5 lymph nodes examined ( P=0.002). Multifactorial Cox regression analysis showed that T stage ( OR=1.408, 95% CI: 1.118-1.670) and the examined number of lymph nodes at N1 station ( OR=0.670, 95% CI: 0.526-0.853) were independent influence factors for the prognosis of pT1-3N0M0 NSCLC patients. Conclusion:The examined number of lymph nodes at the N1 station is associated with the prognosis of patients with pT1-3N0M0 NSCLC, and the examination of at least 5 lymph nodes at N1 station at the time of postoperative pathological examination improves the 5-year survival rate of patients.
Author 徐美青
徐世斌
熊燃
解明然
王高祥
李田
王君
AuthorAffiliation 安徽医科大学附属省立医院 中国科学技术大学附属第一医院胸外科,合肥 230001
AuthorAffiliation_xml – name: 安徽医科大学附属省立医院 中国科学技术大学附属第一医院胸外科,合肥 230001
Author_FL Xu Shibin
Xiong Ran
Xie Mingran
Li Tian
Wang Jun
Wang Gaoxiang
Xu Meiqing
Author_FL_xml – sequence: 1
  fullname: Wang Gaoxiang
– sequence: 2
  fullname: Li Tian
– sequence: 3
  fullname: Xu Shibin
– sequence: 4
  fullname: Wang Jun
– sequence: 5
  fullname: Xiong Ran
– sequence: 6
  fullname: Xu Meiqing
– sequence: 7
  fullname: Xie Mingran
Author_xml – sequence: 1
  fullname: 王高祥
– sequence: 2
  fullname: 李田
– sequence: 3
  fullname: 徐世斌
– sequence: 4
  fullname: 王君
– sequence: 5
  fullname: 熊燃
– sequence: 6
  fullname: 徐美青
– sequence: 7
  fullname: 解明然
BookMark eNotkE1LAlEYhe_CIDN_hsux994779w7y5C-QG1ja7nzVYmN0RCBixCzWvQJ0sIiF7kMyiCQlH7OndF_kVSrszk8h-cskVTYCH1CchTyXFiw4h6ofC3vhpQyisxgwAA4pwYAk2aKpIEhN-ZNa5Fko2jfAZQoTJuKNCmVafLai0dXevSZTLrxoKUvx_HDMHl60-9fhxV6ystQgtlzXw_vksnF9Kw_bY-T3nXcHkxb57OXjr6_TR47-vtDd2-WyUKg6pGf_c8M2VlfqxQ2jeL2xlZhtWhEFAANJZUnAzQZlVJ4wnVtR0iHMgcxcGyPOTxQqABNj9qm7_tIXRRSCAkBt1xu8wzJ_XFPVBiocLdaaxwfhfPFanOvWZ_7_16A_AfurGoZ
ContentType Journal Article
Copyright Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
Copyright_xml – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
DBID 2B.
4A8
92I
93N
PSX
TCJ
DOI 10.3760/cma.j.cn112152-20200331-00284
DatabaseName Wanfang Data Journals - Hong Kong
WANFANG Data Centre
Wanfang Data Journals
万方数据期刊 - 香港版
China Online Journals (COJ)
China Online Journals (COJ)
DatabaseTitleList
DeliveryMethod fulltext_linktorsrc
DocumentTitle_FL Impact of the examined number of lymph nodes at N1 station on the prognosis of patients with pT1-3N0M0 non-small cell lung cancer
EndPage 159
ExternalDocumentID zhzl202202005
GrantInformation_xml – fundername: 国家自然科学基金; 中央高校专项拨款科大新医学联合基金; National Natural Science Foundation of China; Fundamental Research Funds for the Central Universities
  funderid: (81973643); (WK9110000021); (81973643); (WK9110000021)
GroupedDBID ---
-05
123
2B.
4A8
92F
92I
93N
ABDBF
ABJNI
ACGFS
ACUHS
ALMA_UNASSIGNED_HOLDINGS
CCEZO
CIEJG
CW9
EOJEC
OBODZ
PSX
TCJ
TGQ
U1G
U5O
ID FETCH-LOGICAL-s1005-a8ad8f5421887d7cc9b78b12b55fb9d2b3fa5a054d194eee51c5787780f36c393
ISSN 0253-3766
IngestDate Thu May 29 04:03:17 EDT 2025
IsPeerReviewed false
IsScholarly true
Issue 2
Keywords 淋巴结
Clinicopathological characteristics
Prognosis
Lymph node
预后
癌,非小细胞肺
Carcinoma, non-small cell lung
临床病理特征
Language Chinese
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-s1005-a8ad8f5421887d7cc9b78b12b55fb9d2b3fa5a054d194eee51c5787780f36c393
PageCount 5
ParticipantIDs wanfang_journals_zhzl202202005
PublicationCentury 2000
PublicationDate 2022-02-23
PublicationDateYYYYMMDD 2022-02-23
PublicationDate_xml – month: 02
  year: 2022
  text: 2022-02-23
  day: 23
PublicationDecade 2020
PublicationTitle 中华肿瘤杂志
PublicationTitle_FL Chinese Journal of Oncology
PublicationYear 2022
Publisher 安徽医科大学附属省立医院 中国科学技术大学附属第一医院胸外科,合肥 230001
Publisher_xml – name: 安徽医科大学附属省立医院 中国科学技术大学附属第一医院胸外科,合肥 230001
SSID ssib058574917
ssib051368316
ssib007279245
ssib000995398
ssj0042033
ssib006576341
ssib001103529
Score 2.3582275
Snippet 目的:探讨N1站淋巴结检出数目与pT1~3N0M0非小细胞肺癌(NSCLC)患者临床病理特征及预后的关系。方法:选择2013年1月至2015年3月在安徽医科大学附属省立医院接受肺癌根治术的pT1~3N0M0 NSCLC患者337例,采用受试者工作特征(ROC)曲线的分析确定以N1站淋巴结检出数目预测pT1~3N0M0...
SourceID wanfang
SourceType Aggregation Database
StartPage 155
Title N1站淋巴结检出数目对pT1~3N0M0非小细胞肺癌患者预后的影响
URI https://d.wanfangdata.com.cn/periodical/zhzl202202005
Volume 44
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR1NaxQxdCgtiBdRVPwsPZjj1slkMpMcJzuzFKF72kJvZWZ2xiK6im0ve5BSqx78hOKhij3Yo6AVhGKLP2e77b_wvSTdnZaiVViGkPfyPjPJe9kk4zi3sja8YoFb1kJO2zU_5bKWBmFW05-P42lIvRxPI083g6kZ_84snx0ZbVV2LS0tZpN598RzJf_jVagDv-Ip2X_w7IAoVEAZ_AtP8DA8T-XjJiVJSCJFpCRJQFRIhCIJx4LyEaQAxBAUMdzSACDI_VWENRLQXMSRikQJgqIGUfJRi5IwYU13GoCSyJhIDQRc0bAkRUASQQTTICh4mmSIUog60oYaYIggaMWRTuQR4SMdCTWJRo5sjYqJohoEMsbVYJkkPlGCRLEWPNYNDTstiQSQr1WJsRJJNYgczKuIAi3QIlLbSGhjgZ58iGIaG4GAmTuEALUEpTUyyEDjgmr1E-hrtaSqrqBA8o0n0tmgz2sLA7q0pJXRqo4GRblAAG0FUAnKWIhJFGgfyENLUW1xwKxDAmBdb_hbOhoZbJ1odwv3iAXB0ci0ysuwAK0ijRwgZegGpxQjquPPsLC965gYupcA1BBEIw64Q2er6-5i-oSwrgX_HAoPaatrl6DMTOVxhjNVUJ1WzbWedvjwKnMkNfcy23CLmgvhj8_kuFcLXr_8QTp5bzLvULwEBbzm4l5KRmu4VOAPQ5jBxtLufPc-utg1FxuPeSAUzH5jkYpVo5JWSF699hJCYMhDhmF9AEk4q6QJId6yOfz3nVMWCDZMqyDjDn297GEiQN8DGfXarjXLGYdYlW7_USF9cLBTpp27lRi3dd45Z5PTiciMNBecke78RWe6Sftf1ve2X_a2f_R31_Y2l3svdvbeb_U_fu19-wnjxRM9Whx82uhtve3vPt9_urG_stNff7W3srm__Ozg82rv3Zv-h9Xer--9tdeXnJlG0qpP1exHWGoLFG8pTkXaFiX3IRUQYTvMc5mFIqNexnmZybaXsTLlKSR-bSr9oig4zTEICIVbsiBnkl12RjsPO8UVZyLlwi3ykOYl2KsMC5FKtyizogiyNJVMXHXGrfpzdpBdmDvi0Gt_Q7junB2-4Dec0cXHS8VNSBoWs3HbB34DbdHISg
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=N1%E7%AB%99%E6%B7%8B%E5%B7%B4%E7%BB%93%E6%A3%80%E5%87%BA%E6%95%B0%E7%9B%AE%E5%AF%B9pT1%7E3N0M0%E9%9D%9E%E5%B0%8F%E7%BB%86%E8%83%9E%E8%82%BA%E7%99%8C%E6%82%A3%E8%80%85%E9%A2%84%E5%90%8E%E7%9A%84%E5%BD%B1%E5%93%8D&rft.jtitle=%E4%B8%AD%E5%8D%8E%E8%82%BF%E7%98%A4%E6%9D%82%E5%BF%97&rft.au=%E7%8E%8B%E9%AB%98%E7%A5%A5&rft.au=%E6%9D%8E%E7%94%B0&rft.au=%E5%BE%90%E4%B8%96%E6%96%8C&rft.au=%E7%8E%8B%E5%90%9B&rft.date=2022-02-23&rft.pub=%E5%AE%89%E5%BE%BD%E5%8C%BB%E7%A7%91%E5%A4%A7%E5%AD%A6%E9%99%84%E5%B1%9E%E7%9C%81%E7%AB%8B%E5%8C%BB%E9%99%A2%E3%80%80%E4%B8%AD%E5%9B%BD%E7%A7%91%E5%AD%A6%E6%8A%80%E6%9C%AF%E5%A4%A7%E5%AD%A6%E9%99%84%E5%B1%9E%E7%AC%AC%E4%B8%80%E5%8C%BB%E9%99%A2%E8%83%B8%E5%A4%96%E7%A7%91%EF%BC%8C%E5%90%88%E8%82%A5%E3%80%80230001&rft.issn=0253-3766&rft.volume=44&rft.issue=2&rft.spage=155&rft.epage=159&rft_id=info:doi/10.3760%2Fcma.j.cn112152-20200331-00284&rft.externalDocID=zhzl202202005
thumbnail_s http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fzhzl%2Fzhzl.jpg